It has been announced OptiBiotix Health (OPTI) has sold 2.2 million further shares in 2017 spun-off onto AIM SkinBioTherapeutics (SBTX). This despite OptiBiotix’s results earlier this year including “SkinBiotherapeutics plc is making solid progress… As its partnership discussions turn into commercial agreements providing industry validation of its technology we anticipate SkinBiotherapeutics plc will grow in value, whereupon OptiBiotix shareholders will benefit from the appreciation of this asset”. So why the further sale?
Filed under: